Chembio Diagnostics (NASDAQ:CEMI) will release its earnings data after the market closes on Tuesday, August 6th. Analysts expect Chembio Diagnostics to post earnings of ($0.16) per share for the quarter.
Chembio Diagnostics (NASDAQ:CEMI) last announced its earnings results on Wednesday, May 1st. The company reported ($0.14) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.14). The business had revenue of $8.30 million for the quarter, compared to analyst estimates of $8.24 million. Chembio Diagnostics had a negative return on equity of 36.34% and a negative net margin of 29.51%. On average, analysts expect Chembio Diagnostics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ CEMI traded down $0.13 during trading on Tuesday, reaching $5.89. The company’s stock had a trading volume of 432 shares, compared to its average volume of 29,971. The company has a market capitalization of $101.13 million, a PE ratio of -11.05 and a beta of 1.66. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.73 and a quick ratio of 2.38. The stock has a fifty day moving average of $5.95. Chembio Diagnostics has a one year low of $4.85 and a one year high of $11.55.
A number of brokerages have weighed in on CEMI. Benchmark restated a “buy” rating and issued a $130.00 target price (up from $124.00) on shares of TAKE-TWO INTERACTIVE SOFTWARE in a research note on Monday, June 17th. ValuEngine upgraded China Southern Airlines from a “sell” rating to a “hold” rating in a research note on Tuesday, June 11th. Finally, Canaccord Genuity upped their target price on SilverCrest Metals from C$5.75 to C$6.75 in a research note on Monday, July 22nd.
In other news, insider Javan Esfandiari sold 7,300 shares of the stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $7.41, for a total transaction of $54,093.00. Following the transaction, the insider now directly owns 131,473 shares in the company, valued at approximately $974,214.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.90% of the stock is currently owned by corporate insiders.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Featured Article: Gap Up Stocks
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.